795 related articles for article (PubMed ID: 22943064)
1. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
Kolnagou A; Natsiopoulos K; Kleanthous M; Ioannou A; Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):48-56. PubMed ID: 22943064
[TBL] [Abstract][Full Text] [Related]
2. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
Kolnagou A; Yazman D; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
[TBL] [Abstract][Full Text] [Related]
3. The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients.
Kolnagou A; Michaelides Y; Kontoghiorghe CN; Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):34-41. PubMed ID: 23039902
[TBL] [Abstract][Full Text] [Related]
4. A practical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac T2*.
Ha SY; Mok AS; Chu WC; Raskalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2009; 33(5):323-31. PubMed ID: 19814678
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Hemoglobin; 2011; 35(3):186-98. PubMed ID: 21599431
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
[TBL] [Abstract][Full Text] [Related]
7. Effects of combined deferiprone and deferoxamine chelation therapy on iron load indices in beta-thalassemia.
Tsironi M; Assimakopoulos G; Polonofi K; Rigaki K; Aessopos A
Hemoglobin; 2008; 32(1-2):29-34. PubMed ID: 18274980
[TBL] [Abstract][Full Text] [Related]
8. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
[TBL] [Abstract][Full Text] [Related]
9. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
Kolnagou A; Kleanthous M; Kontoghiorghes GJ
Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
[TBL] [Abstract][Full Text] [Related]
10. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
11. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
12. Methods for noninvasive measurement of tissue iron in Cooley's anemia.
Sheth S; Tang H; Jensen JH; Altmann K; Prakash A; Printz BF; Hordof AJ; Tosti CL; Azabagic A; Swaminathan S; Brown TR; Olivieri NF; Brittenham GM
Ann N Y Acad Sci; 2005; 1054():358-72. PubMed ID: 16339684
[TBL] [Abstract][Full Text] [Related]
13. Correlative study of iron accumulation in liver, myocardium, and pituitary assessed with MRI in young thalassemic patients.
Christoforidis A; Haritandi A; Tsitouridis I; Tsatra I; Tsantali H; Karyda S; Dimitriadis AS; Athanassiou-Metaxa M
J Pediatr Hematol Oncol; 2006 May; 28(5):311-5. PubMed ID: 16772883
[TBL] [Abstract][Full Text] [Related]
14. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
Christoforidis A; Haritandi A; Tsatra I; Tsitourides I; Karyda S; Athanassiou-Metaxa M
Eur J Haematol; 2007 Jan; 78(1):52-7. PubMed ID: 17042760
[TBL] [Abstract][Full Text] [Related]
15. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2010 Jun; 34(3):204-9. PubMed ID: 20524810
[TBL] [Abstract][Full Text] [Related]
16. Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study.
Drakonaki EE; Maris TG; Maragaki S; Klironomos V; Papadakis A; Karantanas AH
Hemoglobin; 2010; 34(1):95-106. PubMed ID: 20113293
[TBL] [Abstract][Full Text] [Related]
17. Intermediate-term evaluation of a pratical chelation protocol based on stratification of thalassemic patients by serum ferritin and magnetic resonance imaging cardiac t2*.
Ha SY; Mok AS; Chu WC; Rasalkar DD; Cheuk DK; Chiang AK; Ho MH; Chan GC
Hemoglobin; 2011; 35(3):199-205. PubMed ID: 21599432
[TBL] [Abstract][Full Text] [Related]
18. [Value of magnetic resonance imaging T2* tests in detecting heart and liver iron overload in patients with β-thalassemia major].
Wu X; Jing Y; Pei F; Chen J; Feng X; He Y; Zhang Y; Li C
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Feb; 33(2):249-52. PubMed ID: 23443782
[TBL] [Abstract][Full Text] [Related]
19. Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major patients.
Cassinerio E; Roghi A; Pedrotti P; Brevi F; Zanaboni L; Graziadei G; Pattoneri P; Milazzo A; Cappellini MD
Ann Hematol; 2012 Sep; 91(9):1443-9. PubMed ID: 22572843
[TBL] [Abstract][Full Text] [Related]
20. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
